Ascendis Pharma A/s Earnings

Ascendis Pharma A/s’s revenue jumped 5.28% since last year same period to $100.95Mn in the Q1 2025. On a quarterly growth basis, Ascendis Pharma A/s has generated -41.95% fall in its revenue since last 3-months.

Ascendis Pharma A/s’s net profit jumped 27.79% since last year same period to $-94.63Mn in the Q1 2025. On a quarterly growth basis, Ascendis Pharma A/s has generated -145.98% fall in its net profits since last 3-months.

Ascendis Pharma A/s’s net profit margin jumped 31.41% since last year same period to -93.73% in the Q1 2025. On a quarterly growth basis, Ascendis Pharma A/s has generated -323.76% fall in its net profit margins since last 3-months.

Ascendis Pharma A/s’s earning per share (EPS) estimates for the current quarter stand at -1.51 - a -61.41% fall from last quarter’s estimates.

Ascendis Pharma A/s’s earning per share (EPS) estimates for the current year stand at -1.51.

Ascendis Pharma A/s’s earning per share (EPS) jumped 31.3% since last year same period to -1.58 in the Q1 2025. This indicates that the Ascendis Pharma A/s has generated 31.3% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ascendis Pharma A/s’s return on assets (ROA) stands at -0.22.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ascendis Pharma A/s’s return on equity (ROE) stands at -8.18.